BiotechTube
Home/Pipeline/ATOR-4066

ATOR-4066

Undisclosed Solid Tumors

Discovery/PreclinicalPlatform-derived asset

Key Facts

Indication
Undisclosed Solid Tumors
Phase
Discovery/Preclinical
Status
Platform-derived asset
Company
Alligator Bioscience AB

About Alligator Bioscience AB

Alligator Bioscience is a clinical-stage biotech focused on developing tumor-directed antibody therapies for cancer. Its core strategy is built on proprietary platforms like ALiCE® and RUBY™ to generate highly specific, next-generation immuno-oncology drugs. The company's most advanced program, mitazalimab (a CD40 agonist), is in a pivotal Phase 2/3 trial for metastatic pancreatic ductal adenocarcinoma (PDAC), representing a significant near-term value inflection point. Alligator operates as an R&D-centric organization, advancing its pipeline through internal development and strategic partnerships.

View full company profile

Therapeutic Areas

Oncology

Other Undisclosed Solid Tumors Drugs

DrugCompanyPhase
Macrophage-Targeting Agonist AntibodyBolt BiotherapeuticsPhase 1
IMA204Immatics BiotechnologiesPhase 1
TAR002TargImmune TherapeuticsPre-clinical
TAR003TargImmune TherapeuticsPre-clinical
ERAS-113ErascaDiscovery
Multiple ProgramsAktis OncologyDiscovery
BAT5506CompugenPreclinical
Precision DACsPrelude TherapeuticsDiscovery
V2ACT ImmunotherapyGeneluxPhase 1
ACR-6840Acrivon TherapeuticsPreclinical
ADC ProgramLantern PharmaDiscovery/Preclinical
Albumin Shield™-Enabled OVTheriva BiologicsPreclinical